Limits...
Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.

Becker M, Tschechne B, Reeb M, Schwinger U, Bruch HR, Frank M, Straßl L - Ann. Hematol. (2015)

Bottom Line: The overall response rate was 86 % (complete response 43 %, partial response 43 %, stable disease 10 %, progressive disease 4 %).Side effects of all grades were documented for 161 of the 323 patients (50 %), most frequently affecting blood/bone marrow (35 %).Fifty-four (17 %) patients experienced side effects of grade 3 (15 %) or grade 4 (2 %), and two patients grade 5 toxicities.

View Article: PubMed Central - PubMed

Affiliation: Onkologische Praxis Minden-Porta, Flurweg 13, 32457, Porta Westfalica, Germany.

ABSTRACT
Bendamustine has demonstrated clinical activity and a favorable safety profile as monotherapy or in combination with rituximab in lymphoid malignancies. As interventional trials do not always reflect clinical reality, we were interested in the treatment modalities and the outcome of bendamustine-based first-line therapy in patients with advanced indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) in routine practice. Between April 2010 and October 2011, 324 patients were enrolled in a prospective non-interventional multicenter study. Choice of the bendamustine regimen was at the treating physician's discretion. Effectiveness was assessed by best response. Mean age at onset of therapy was 69 years. The majority (94 %) of the patients was treated with bendamustine in combination with rituximab at a median bendamustine dose of 177 mg/m(2) per cycle. Most often, bendamustine was administered on days 1 and 2 (87 %) at 4-week intervals over a median of 6 cycles. Two hundred eighty-one patients qualified for evaluation of response. The overall response rate was 86 % (complete response 43 %, partial response 43 %, stable disease 10 %, progressive disease 4 %). Side effects of all grades were documented for 161 of the 323 patients (50 %), most frequently affecting blood/bone marrow (35 %). Fifty-four (17 %) patients experienced side effects of grade 3 (15 %) or grade 4 (2 %), and two patients grade 5 toxicities. Bendamustine-based first-line treatment of patients with advanced indolent NHL and MCL in clinical routine practice was assessed as effective and well tolerated in our study. Response was comparable to results from interventional clinical trials.

Show MeSH

Related in: MedlinePlus

Trial profile
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4525187&req=5

Fig1: Trial profile

Mentions: Between April 2010 and October 2011, 324 patients were enrolled in 57 German centers. Patients who had received at least one dose of bendamustine were included in the safety analysis set (n = 323). For the general analysis set (n = 307), 16 additional patients with a diagnosis of CLL or aggressive lymphoma were excluded. Different analysis sets were necessary for response rate (n = 281) and treatment duration (n = 277), respectively, as the observation period and/or bendamustine therapy for some patients was not completed at the end of the study on 31 December 2011 (Fig. 1).Fig. 1


Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice.

Becker M, Tschechne B, Reeb M, Schwinger U, Bruch HR, Frank M, Straßl L - Ann. Hematol. (2015)

Trial profile
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4525187&req=5

Fig1: Trial profile
Mentions: Between April 2010 and October 2011, 324 patients were enrolled in 57 German centers. Patients who had received at least one dose of bendamustine were included in the safety analysis set (n = 323). For the general analysis set (n = 307), 16 additional patients with a diagnosis of CLL or aggressive lymphoma were excluded. Different analysis sets were necessary for response rate (n = 281) and treatment duration (n = 277), respectively, as the observation period and/or bendamustine therapy for some patients was not completed at the end of the study on 31 December 2011 (Fig. 1).Fig. 1

Bottom Line: The overall response rate was 86 % (complete response 43 %, partial response 43 %, stable disease 10 %, progressive disease 4 %).Side effects of all grades were documented for 161 of the 323 patients (50 %), most frequently affecting blood/bone marrow (35 %).Fifty-four (17 %) patients experienced side effects of grade 3 (15 %) or grade 4 (2 %), and two patients grade 5 toxicities.

View Article: PubMed Central - PubMed

Affiliation: Onkologische Praxis Minden-Porta, Flurweg 13, 32457, Porta Westfalica, Germany.

ABSTRACT
Bendamustine has demonstrated clinical activity and a favorable safety profile as monotherapy or in combination with rituximab in lymphoid malignancies. As interventional trials do not always reflect clinical reality, we were interested in the treatment modalities and the outcome of bendamustine-based first-line therapy in patients with advanced indolent non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL) in routine practice. Between April 2010 and October 2011, 324 patients were enrolled in a prospective non-interventional multicenter study. Choice of the bendamustine regimen was at the treating physician's discretion. Effectiveness was assessed by best response. Mean age at onset of therapy was 69 years. The majority (94 %) of the patients was treated with bendamustine in combination with rituximab at a median bendamustine dose of 177 mg/m(2) per cycle. Most often, bendamustine was administered on days 1 and 2 (87 %) at 4-week intervals over a median of 6 cycles. Two hundred eighty-one patients qualified for evaluation of response. The overall response rate was 86 % (complete response 43 %, partial response 43 %, stable disease 10 %, progressive disease 4 %). Side effects of all grades were documented for 161 of the 323 patients (50 %), most frequently affecting blood/bone marrow (35 %). Fifty-four (17 %) patients experienced side effects of grade 3 (15 %) or grade 4 (2 %), and two patients grade 5 toxicities. Bendamustine-based first-line treatment of patients with advanced indolent NHL and MCL in clinical routine practice was assessed as effective and well tolerated in our study. Response was comparable to results from interventional clinical trials.

Show MeSH
Related in: MedlinePlus